John Kaczmar to Head and Neck Neoplasms
This is a "connection" page, showing publications John Kaczmar has written about Head and Neck Neoplasms.
Connection Strength
1.085
-
HPV-negative head and neck squamous cell carcinomas: how can we use the tumor protein signature? Biomark Med. 2015; 9(3):183-5.
Score: 0.340
-
Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2022 04 01; 28(7):1345-1352.
Score: 0.141
-
Development and Evaluation of a Navigation-Based, Multilevel Intervention to Improve the Delivery of Timely, Guideline-Adherent Adjuvant Therapy for Patients With Head and Neck Cancer. JCO Oncol Pract. 2021 10; 17(10):e1512-e1523.
Score: 0.131
-
Microscopic Extranodal Extension in HPV-Negative Head and Neck Cancer and the Role of Adjuvant Chemoradiation. Otolaryngol Head Neck Surg. 2021 10; 165(4):536-549.
Score: 0.130
-
Evaluating Adjuvant Therapy With Chemoradiation vs Radiation Alone for Patients With HPV-Negative N2a Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2020 12 01; 146(12):1109-1119.
Score: 0.128
-
Barriers to the Delivery of Timely, Guideline-Adherent Adjuvant Therapy Among Patients With Head and Neck Cancer. JCO Oncol Pract. 2020 12; 16(12):e1417-e1432.
Score: 0.126
-
Phospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck. Oncotarget. 2015 Aug 07; 6(22):18863-74.
Score: 0.089